IV

• RUSTON, La., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue third quarter 2023 results after the market closes on Wednesday, October 25, 2023, and hold a conference call to discuss such results on Thursday, October 26, 2023, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).
• The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank.
• To participate in the live conference call, please dial +1 (929) 272-1574 (U.S. Local / International 1); +1 (857) 999-3259 (U.S. Local / International 2); +1 (800) 528-1066 (U.S. Toll Free), enter Conference ID: 51465 and request to be joined into the Origin Bancorp, Inc. (OBK) call.
• A simultaneous audio-only webcast may be accessed via Origin’s website at www.origin.bank under the investor relations, News & Events, Events & Presentations link or directly by visiting https://dealroadshow.com/e/ORIGINQ323 .

• By then, four hospitals had already ceased functioning in Gaza’s north due to damage from Israeli bombs.
• Insufficiently and poorly resourced for decades, doctors and hospitals also had to contend with the devastating effects of a 16-year blockade imposed by Israel, in part with coordination with Egypt.

A system completely overwhelmed

• Hospitals in Gaza are completely overwhelmed.
• They are seeing around 1,000 new patients per day, in a health system with only 2,500 hospital beds for a population of over 2 million people.
• People maimed in the bombing are being treated for horrific injuries without basics such as gauze dressings, antiseptic, IV bags and painkillers.
• The U.N. estimates this fuel will run out any day due to a complete siege placed on Gaza by Israel.

A century of underfunding

• But Gaza’s health care system was already under stress before the latest bombardment.
• In fact, policies that stretch back decades have left it unable to meet even the basic health needs of Gaza’s residents, let alone respond to the ongoing humanitarian catastrophe.
• What each have had in common is that, from my perspective as a global health expert, they invested little in Palestinian health.
• For periods of the 20th century, the health priorities of successive governing bodies appeared focused more on reducing the spread of communicable disease to protect foreigners interacting with the native Palestinian population.

Dying before they can leave

• Since then, chronic underfunding of public hospitals has meant that Palestinians in Gaza have remained reliant on outside money and nongovernmental organizations for essential health services.
• During the passage of the Oslo Accords in the mid-1990s, the Palestinian Authority was established to administer services in the occupied territories.
• The Palestinian Authority received a significant influx of humanitarian aid as it took on civil responsibilities, including health.
• As a result, health indicators for Palestinians, including life expectancy and immunization rates, started to improve in the late 1990s.

Gaza health services after the siege

• It is uncertain what the health system of Gaza will look like in the future.
• Already at least 28 doctors and other health workers have been killed in Gaza, with ambulances and a number of hospitals rendered useless by the bombs.

• Study results demonstrate the effect of Ocrevus® (ocrelizumab) as an investigational twice-yearly, 10-minute subcutaneous injection on pharmacokinetic, biomarker, and MRI measures in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS).
• “We are pleased to share that Ocrevus 10-minute subcutaneous injection suppressed brain lesions as effectively as the intravenous infusion,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.
• Peak Ocrevus blood (serum) concentrations were similar for subcutaneous injection (132 µg/mL) and IV infusion (137 µg/mL).
• Ocrevus subcutaneous injection provided rapid, sustained and near-complete B-cell depletion that was similar to Ocrevus IV infusion (97% and 98% of patients respectively had B cell levels of 5 cells/µL or less when first measured at 14 days), which was sustained over 24 weeks.

• SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1
  Risankizumab showed superiority versus ustekinumab for all ranked secondary endpoints, including achievement of clinical remissiona at week 48, achievement of endoscopic responsec at week 48 and 24, achievement of steroid-free endoscopic remissiond at week 48 and achievement of steroid-free clinical remissione at week 481
  Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified
  NORTH CHICAGO, Ill., Oct. 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI®, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA®, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.1 The data were presented at the United European Gastroenterology (UEG) Week 2023, October 14-17.
• "At AbbVie, we are committed to developing medicines and generating evidence that advance care for people living with immune-mediated conditions, including inflammatory bowel diseases," said Roopal Thakkar, M.D., senior vice president, development and regulatory affairs and chief medical officer, AbbVie.
• "Results such as these not only help differentiate SKYRIZI as an option for managing Crohn's disease, but also may help to evolve the field by further informing on therapeutic strategies for patients."
• The SEQUENCE study included two sequentially tested primary endpoints:
  The results of the first primary endpoint, clinical remission (CDAI The results of the second primary endpoint, endoscopic remission (Simple Endoscopic Score for Crohn's disease [SES-CD] ≤4 and at least a 2-point reduction versus baseline and no sub-score greater than 1 in any individual component) at week 48 demonstrated superiority with risankizumab compared to ustekinumab with remission rates of 32% in risankizumab group and 16% in ustekinumab group (p Additionally, risankizumab demonstrated superiority compared to ustekinumab for all ranked secondary endpoints, including achievement of clinical remission at week 48, achievement of endoscopic response at week 48 and 24, achievement of steroid-free endoscopic remission at week 48, and achievement of steroid-free clinical remission at week 48.1